744679
Last Update Posted: 2015-02-10
Recruiting has ended
All Genders accepted | 18 Years-55 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state.
The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady state.
Eligibility
Relevant conditions:
Multiple Sclerosis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov